PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus
Condition: Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris Interventions: Drug: Cutaneous lichen planus secukinumab 300 mg Q4W; Drug: Cutaneous lichen planus placebo; Drug: Mucosal lichen planus placebo; Drug: Lichen planopilaris placebo; Drug: Mucosal lichen planus secukinumab 300 mg Q4W; Drug: Lichen planopilaris secukinumab 300 mg Q4 W Sponsor: Novartis Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials